Skip to main content

Table 3 Multivariate analysis

From: Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study

Time

Risk factor

RR

p-value

First six months period day 0–182 since first R dose

Nadir ≥0.13 ×109 /L

1.00

 

Nadir <0.13 Ă—109 /L

1.89 (1.00-3.60)

0.051

HIV neg.

1.00

 

HIV pos.

2.92 (1.11-7.65)

0.030

no GVHD

1.00

 

GVHD

1.49 (0.52-4.27)

0.453

Indolent lymphoma

1.00

 

Aggressive lymphoma

2.76 (1.34-5.670

0.006

Non-CD20 malignancy

1.56 (0.56-4.33)

0.394

Second six months period day 183–364 since first R dose

Nadir ≥0.13 ×109 /L

1.00

 

Nadir <0.13 Ă—109 /L

2.68 (1.19-6.04)

0.017

HIV neg.

1.00

 

HIV pos.

1.21 (0.27-5.38)

0.798

no GVHD

1.00

 

GVHD

7.22 (2.38-21.92)

<0.001

Indolent lymphoma

1.00

 

Aggressive lymphoma

1.21 (0.48-3.02)

0.687

Non-CD20 malignancy

1.57 (0.49-4.98)

0.447

Third six months period day 364–546 since first R dose

Nadir ≥0.13 ×109 /L

1.00

 

Nadir <0.13 Ă—109 /L

2.54 (1.07-6.02)

0.034

HIV neg.

1.00

 

HIV pos.

1.49 (0.33-6.67)

0.601

no GVHD

1.00

 

GVHD

3.65 (1.11-12.04)

0.034

Indolent lymphoma

1.00

 

Aggressive lymphoma

1.53 (0.60-3.91)

0.371

Non-CD20 malignancy

0.93 (0.25-3.42)

0.908

  1. The model allows interaction with time since first Rituximab administration and each risk factor. The analysis provides moderate to strong evidence that all the 4 risk factors were associated with the infections in a time dependent manner; i.e.: HIV and type of diagnosis were associated with increased risk of infection in first six months only, GVHD in the second and third time periods while counts of lymphocytes at nadir was associated with increased risk for all the 3 time periods.
  2. HSCT hematopoietic stem cell transplant, HIV antibody against human immunodeficiency virus, GVHD graft versus host disease, R Rituximab, CHT chemotherapy, IQR inter-quartile range, RR rate ratio, 95%CI 95% confidence interval.